PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Decitabine

Drugs in development · updated 30 October 2026

Decitabine: clinical trials and development status

Other names and codes: Dacogen

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 20 September 2012

As of 30 October 2026 Decitabine is in 123 active clinical trials (recruiting or ongoing, phases I–III) for 39 diseases. The most advanced phase is III.

123Active trials
IIIMost advanced phase
39Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Decitabine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 39 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII59NCT05586074
Myelodysplastic SyndromesIII29NCT05883956
Chronic myelomonocytic leukemiaIII11NCT05883956
Diffuse large B-cell lymphomaIII6NCT07348575
Patient preferenceIII1NCT05883956
LeukemiaII6NCT07060001
Myeloproliferative disordersII5NCT05564390
Myelodysplastic–myeloproliferative diseasesII4NCT06661915
MyelofibrosisII4NCT06661915
Ovarian neoplasmII4NCT05983276
Acute biphenotypic leukaemiaII2NCT04975919
Acute monocytic leukemiaII2NCT04282187
Acute myelomonocytic leukemiaII2NCT00801489
Fallopian tube neoplasmI–II2NCT02650986
Hodgkin lymphomaII2NCT03418038
LymphomaII2NCT03418038
Polycythemia veraII2NCT06661915
Precursor T-cell lymphoblastic leukemiaII2NCT06561074
Refractory anemia with excess of blastsII2NCT00801489
Thrombocythemia, EssentialII2NCT06661915
Acute basophilic leukemiaII1NCT01627041
Breast neoplasmII1NCT02957968
Burkitt lymphomaII1NCT06393985
Chronic phase chronic myelogenous leukemiaII1NCT05007873
Congenital bone marrow failure syndromesII1NCT05796570
Malignant mesotheliomaII1NCT05960773
MelanomaI–II1NCT02650986
MesotheliomaII1NCT05960773
NeoplasmI–II1NCT02961101
Pancreatic neoplasmI–II1NCT06454448

Everything on Decitabine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch